Elanco Animal Health Incorporated
ELANHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Elanco Animal Health Incorporated focuses on Drug Manufacturers - Specialty & Generic services and products. Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. Valued at $12.24B, ELAN is a large-cap name in its sector. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark.
Market Cap
$12.24B
Beta
1.68
P/E (TTM)
—
P/E (Fwd)
19.15
EPS (TTM)
$-0.41
EPS (Fwd)
$1.28
ROE
-3.0%
ROA
1.6%
Cash
$530.0M
Total Debt
$4.23B
Free CF
$826.9M
52W Change
30.6%
Annual Financials
Cash vs Debt
Where ELAN stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, ELAN finished 0.42% below its 150-day moving average ($24.01) and 0.93% above its 200-day moving average ($23.69). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ELAN overbought or oversold?
At the September 2, 2026 close, ELAN's RSI(14) was 64.5, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, ELAN has $530.0M in cash with $4.23B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $826.9M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -3.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.6% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $4.41B (2022) to $4.71B (2025).
A beta of 1.68 means ELAN is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ELAN.